METHOD FOR DIAGNOSING A SKIN DISPLAYING SIGNS OF DRYNESS

Abstract

The present invention relates to a method for diagnosing a skin displaying signs of dryness, based on the measurement of the level of expression of the gene encoding LCN1. The present invention also relates to a method for the cosmetic treatment of skin. The present invention also relates to a method for identifying a compound suitable for reducing and/or slowing the progression of the signs of dryness of a skin, as well as a kit.

Claims

1. A method for diagnosing a skin displaying signs of dryness, in a subject, said method comprising measuring the level of expression of the gene encoding LCN1, in a skin sample from said subject.

2. A method for the cosmetic treatment of a skin displaying signs of dryness in a subject, said method comprising the following: a) measuring the level of expression of the gene encoding LCN1, in a skin sample from said subject; b) inferring from step a) whether said subject's skin displays signs of dryness; c) if the skin is identified as displaying signs of dryness in step b), treating said skin with a cosmetic composition suitable for reducing and/or slowing the progression of the signs of skin dryness.

3. A method for identifying a compound suitable for reducing and/or slowing the progression of the signs of dryness of a skin, said method comprising the following: a) measuring the level of expression of the gene encoding LCN1, in a skin sample exposed to a candidate compound; b) comparing said level of expression measured in step a) to the level of expression of the gene encoding LCN1 in a skin sample not exposed to said compound; c) identifying said candidate compound as a compound suitable for reducing and/or slowing the progression of the signs of dryness of a skin when an increase in the level of expression of the gene encoding LCN1 in the skin sample exposed to said candidate compound is detected, with respect to the level of expression of the gene encoding LCN1 in the skin sample not exposed to the candidate compound.

4. The method according to claim 3, wherein said skin sample is a skin cell culture, an epidermis culture, a reconstructed whole skin, a human skin explant, or a skin sample from a subject.

5. The method according to claim 1, wherein the skin sample is taken using a D-squame disc.

6. The method according to claim 1, wherein the level of expression of the gene encoding LCN1 is determined by the level of expression of mRNA of said gene or by measuring the level of expression of the protein encoded by said gene, preferably by measuring the level of expression of the protein encoded by said gene.

7. The method according to claim 6, wherein the level of expression of the protein encoded by the gene encoding LCN1 is measured using at least one specific ligand of LCN1 protein.

8. A kit comprising: a) means for detecting, in a skin sample, the expression of the gene encoding LCN1, and b) an instruction leaflet c) means for taking a skin sample.

9. The kit according to claim 8 wherein the means for detecting, in a skin sample, the expression of the gene encoding LCN1 is at least a specific ligand of LCN1, preferably a pair of capture and detection antibodies specific for LCN1 protein.

10. A method for identifying a compound suitable for reducing and/or slowing the progression of the signs of dryness of a skin which comprises using the kit according to claim 8.

11. A method for identifying a compound suitable for reducing and/or slowing the progression of the signs of dryness of a skin which comprises using the kit according to claim 9.

12. The method according to claim 2, wherein the skin sample is taken using a D-squame disc.

13. The method according to claim 3, wherein the skin sample is taken using a D-squame disc.

14. The method according to claim 4, wherein the skin sample is taken using a D-squame disc.

15. The method according to claim 2, wherein the level of expression of the gene encoding LCN1 is determined by the level of expression of mRNA of said gene or by measuring the level of expression of the protein encoded by said gene, preferably by measuring the level of expression of the protein encoded by said gene.

16. The method according to claim 3, wherein the level of expression of the gene encoding LCN1 is determined by the level of expression of mRNA of said gene or by measuring the level of expression of the protein encoded by said gene, preferably by measuring the level of expression of the protein encoded by said gene.

17. The method according to claim 4, wherein the level of expression of the gene encoding LCN1 is determined by the level of expression of mRNA of said gene or by measuring the level of expression of the protein encoded by said gene, preferably by measuring the level of expression of the protein encoded by said gene.

18. The method according to claim 5, wherein the level of expression of the gene encoding LCN1 is determined by the level of expression of mRNA of said gene or by measuring the level of expression of the protein encoded by said gene, preferably by measuring the level of expression of the protein encoded by said gene.

19. The method according to claim 15, wherein the level of expression of the protein encoded by the gene encoding LCN1 is measured using at least one specific ligand of LCN1 protein.

20. The method according to claim 16, wherein the level of expression of the protein encoded by the gene encoding LCN1 is measured using at least one specific ligand of LCN1 protein.

Description

EXAMPLE

[0046] The level of visible skin dryness was evaluated on the cheeks of 376 women aged 36 to 75 years. The level of protein expression of the gene encoding LCN1 was also evaluated on these women's cheeks, by means of a D-squame sample wherein the soluble protein extract was analyzed using an ELISA test conducted on a chip.

[0047] The univariate statistical analysis of the results obtained shows a correlation between the presence of these signs of dryness and the expression of LCN1 protein.

TABLE-US-00001 TABLE 1 threshold value (in clinical signs accuracy sensitivity specificity ng/ml) dryness 49% 69% 43% 72.23